Investor Newsletter

Issue 04 2021

MicroPort®

Horizon Medical® Orkid® Intrauterine Insemination Catheter Approved for Marketing

The Orkid® intrauterine insemination catheter ("Orkid®"), a product by Shanghai Horizon Medical Technology Co., Ltd. ("Horizon Medical®"), has recently received the registration certificate from the Shanghai Municipal Drug Administration.

The Orkid® intrauterine insemination catheter is suitable for intrauterine insemination (IUI) in assisted reproductive technologies. With a soft, smooth tip, the catheter minimizes discomfort effectively and transports the sperm gently when entering the uterus cavity. The product has undergone rigorous positive and negative pressure tests to ensure no intraoperative fluid or air leak. The product is available in straight and curved versions to meet the different clinical needs.

Previously, the Lotus™ single-use sterile ovum aspiration needle and Daylily® embryo transfer catheter, two proprietary products developed by Horizon Medical®, have been approved for marketing and launched in China. Both products have been highly recognized by experts in clinical practice.

Dr. Guo Zong, General Manager of Horizon Medical®, said, "The approval of Orkid® marks further diversification of the Horizon Medical® product portfolio in the field of assisted reproduction. In the future, Horizon Medical® will continue to pursue innovative research and development in conjunction with the clinical needs of patients and doctors, providing doctors with safer and more reliable solutions and to bring patients with the hope of conceiving new lives."

MicroPort CRM Receives CE Mark Approval for Alizea™ and Borea™ Pacemakers under the New European Medical Device Regulation

MicroPort CRM announces it has received CE Mark approval under the new MDR (Medical Device Regulation – 2017/745) for its latest range of implantable pacemakers, AlizeaTM and BoreaTM, as well as for the SmartView ConnectTM home monitor. These devices are equipped with Bluetooth® technology for advanced wireless remote monitoring.

"We are very proud to be the first company to affix a CE mark to a range of pacemakers under the new European Medical Device Regulation (MDR)," said Vincent Leveaux, VP Product Development at MicroPort CRM. "TÜV SÜD Product Service GmbH, as the Notified Body, carried out the attestation of conformity under the new regulation and helped us to comply with all applicable regulations. The Declaration of Conformity gives an element of safety to customers in all European markets, as it states that essential requirements to ensure the protection of health have been met in the manufacture and that it is a safe and high quality product."

Alizea™ and Borea™ pacemakers are provided with SmartView Connect™ home monitor which is to be placed at the patient's bedside. The monitor will allow cardiologists to automatically and regularly receive detailed reports on the functioning of the system, saving patients the need to travel to hospital for a simple routine examination.



Alizea™ and Borea™ pacemakers

SmartView Connect™ home monitor

MicroPort

Subject Enrollment Completed for Clinical Trial of MicroPort® EP Contact Force-Sensing Catheter

Subject enrollment for the pre-market clinical trial of the MicroPort® Contact Force-Sensing RF Ablation Catheter ("Contact Force-Sensing Catheter"), developed by Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP"), has been completed. The final operation under the trial was performed by Huimin Chu's team in the Department of Cardiovascular Medicine at Ningbo First Hospital on March 30th, using the Contact Force-Sensing Catheter in combination with the Columbus® 3D EP Navigation System.

The clinical trial of the Contact Force-Sensing Catheter is a prospective, multi-center clinical study designed to evaluate the safety and efficacy of the pressure monitoring function of the catheter, the tubing set and the 3D EP navigation system developed and manufactured by MicroPort® EP for atrial fibrillation clinical applications. The First Hospital of Dalian Medical University is leading the study in collaboration with the First Hospital of Ningbo, the First People's Hospital of Shanghai, Shanghai Oriental Hospital, and Xuzhou Central Hospital.

The Contact Force-Sensing Catheter used in this clinical trial provides surgeons with real-time force values of the catheter where it comes in contact with the inner wall of the cardiac cavity during atrial fibrillation ablation procedures. Compared with conventional 3D catheters, it can shorten procedure time, reduce complications, and X-ray damage to both the patient and the surgeon. The Catheter also helps to shorten the learning curve for newly trained surgeons.

Currently, this catheter has passed the special approval process of the NMPA for innovative medical devices and is expected to become the first domestic contact force-sensing catheter to be certified for marketing in China. In the future, MicroPort® EP will continue to invest more resources in innovative research and development, as well as clinical trials, to provide better integrated solutions for patients and doctors.

MicroPort



MicroPort® NeuroTech Closes Equity Investment in Rapid Medical, Becoming a Majority Shareholder

Shanghai MicroPort® NeuroTech Co., Ltd. ("MicroPort® NeuroTech") has recently closed an equity investment deal with Rapid Medical. As the lead investor in the Series D funding round, MicroPort® NeuroTech, together with CPE, Deep Insight and existing investors of Rapid Medical, will place a strategic investment totaling USD 50 million in Rapid Medical., MicroPort® NeuroTech will become a majority shareholder in Rapid Medical upon completion of the investment.

Rapid Medical is an innovative medical device company based in Israel that specializes in the development, production and marketing of medical devices for neuroendovascular therapy. MicroPort® NeuroTech became a shareholder of Rapid Medical through capital investment in April 2019 and has since become the exclusive distributor of three flagship products of Rapid Medical in Greater China, namely the Tigertriever® Adjustable Clot Retriever, Comaneci® Aneurysm Embolization Assist Device and Tigertriever® 13, responsible for their registration and marketing in the region. All three products have received CE mark and have been used in clinical practice in Europe. The Tigertriever® Adjustable Clot Retriever and the Comaneci® Aneurysm Embolization Assist Device have been approved by the FDA. In addition, the Tigertriever® was approved by the National Medical Products Administration of China (NMPA) in May 2020 and entered the special approval procedure for innovative medical devices (the "Green Channel").

"It is very exciting to enter into further collaboration with MicroPort® NeuroTech at a critical time in the development of Rapid Medical. We believe that as collaboration deepens, both companies will work together to advance the promotion and use of our products in the global market," said Ronen Eckhouse, Co-founder and CEO of Rapid Medical.

As the product lines of MicroPort® NeuroTech and Rapid Medical are highly complementary, this round of strategic investment will further strengthen the cooperation between the two companies. Yiqun Wang, Executive Vice President of MicroPort® NeuroTech, said, "MicroPort® NeuroTech and Rapid Medical will fully consolidate their market resources at home and abroad towards a complete and diverse portfolio of hemorrhagic and ischemic products. We will continue to launch and promote our products in Europe, the Americas, the Asia Pacific and other global markets, and provide a total solution provider for cerebral apoplexy to benefit doctors and patients worldwide."

MicroPort

MicroPort® Wins German iF Product Design Award

The Percutaneous Puncture Robot designed by the Industrial Design Centre of MicroPort (Shanghai) has beaten nearly 10,000 other entries to be awarded the 2021 German iF Product Design Award. Launched in 1953, the iF Design Award is the longest-standing industrial design institution in Germany. The winners receive the prestigious accolade of the iF logo.

The award-winning MicroPort® Percutaneous Puncture Robot was a collaborative effort by three teams working on industrial design, interactive design, and 3D animation design. The robot's unibody design improves sealing performance, reduces liquid damage during product sterilization and cleaning, and improves service life, whilst the reduced grooves and gaps make it easy to sterilize and clean. The improved needle holder morphology enables simple installation and precise positioning by factoring in the need for double-sided use. The enhanced user interface design improves user experience by optimizing the logic flow and simplifying operations, thus reducing the learning curve of doctors.

MicroPort

MicroPort® Among First to be Named "Medical Device Education Base" by the NMPA Institute of Executive Development

Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") was named an "education base" by the National Medical Products Administration (NMPA) Institute of Executive Development at an unveiling ceremony, held in Shanghai on April 7, 2021. MicroPort® is one of the first seven entities awarded the title of "Medical Device Education Base".

The NMPA Institute of Executive Development is an authoritative and professional education and training institution in the field of medical product supervision in China. In 2020, the Institute selected 15 enterprises as education bases for different areas, including pharmaceutical products and medical devices, to enhance the professional qualification and legal awareness of practitioners in the field of drug supervision, as well as strengthen their sense of responsibility and expand their horizons. These education bases, which are carefully selected from institutions nominated by local drug administrations, will provide practical training for supervisory professionals in their respective fields, further enhancing the professionalism of China's drug and medical device supervision.

Yong Li, Senior Vice President of Quality at MicroPort®, said, "In the future, MicroPort® will continue to maximize its role as a practical training base, continuously improve the training system, innovate teaching methods and approaches, enhance training and teaching quality, strive to become a role model for the development of the industry, support strengthening the capacity development of the regulatory workforce, and contribute enhancing the specialization and professionalism in the field of medical device supervision."



MicroPort

Investor Newsletter

Issue 04 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com